| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Blood
|
2006
|
8.38
|
|
2
|
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
7.83
|
|
3
|
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
|
Blood
|
2008
|
6.39
|
|
4
|
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
|
Blood
|
2010
|
4.51
|
|
5
|
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
|
Cancer
|
2006
|
4.04
|
|
6
|
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
|
J Clin Oncol
|
2008
|
2.54
|
|
7
|
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
|
Blood
|
2010
|
2.25
|
|
8
|
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
|
Clin Cancer Res
|
2006
|
2.23
|
|
9
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Blood
|
2010
|
2.19
|
|
10
|
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
|
Cancer
|
2013
|
2.06
|
|
11
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Blood
|
2004
|
2.03
|
|
12
|
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
2.02
|
|
13
|
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.95
|
|
14
|
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
|
Blood
|
2007
|
1.87
|
|
15
|
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.85
|
|
16
|
Clofarabine combinations as acute myeloid leukemia salvage therapy.
|
Cancer
|
2008
|
1.77
|
|
17
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
|
Leuk Lymphoma
|
2014
|
1.77
|
|
18
|
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
|
Blood
|
2003
|
1.76
|
|
19
|
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
|
Blood
|
2006
|
1.73
|
|
20
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
Clin Cancer Res
|
2004
|
1.68
|
|
21
|
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
|
Leuk Lymphoma
|
2009
|
1.59
|
|
22
|
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
|
Leuk Res
|
2009
|
1.57
|
|
23
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
24
|
Pneumonia during remission induction chemotherapy in patients with acute leukemia.
|
Ann Am Thorac Soc
|
2013
|
1.51
|
|
25
|
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells.
|
Leuk Lymphoma
|
2012
|
1.48
|
|
26
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.42
|
|
27
|
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
|
Leuk Lymphoma
|
2007
|
1.42
|
|
28
|
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
|
Cancer
|
2011
|
1.42
|
|
29
|
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
|
Cancer
|
2009
|
1.27
|
|
30
|
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.25
|
|
31
|
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
|
Cancer
|
2008
|
1.18
|
|
32
|
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
|
Cancer
|
2009
|
1.15
|
|
33
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Haematologica
|
2012
|
1.10
|
|
34
|
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
|
Cancer
|
2004
|
1.07
|
|
35
|
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.06
|
|
36
|
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
|
Blood
|
2003
|
1.06
|
|
37
|
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.06
|
|
38
|
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
1.04
|
|
39
|
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
|
Blood
|
2009
|
1.03
|
|
40
|
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
|
Cancer
|
2006
|
1.01
|
|
41
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
Leuk Res
|
2006
|
1.00
|
|
42
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Cancer
|
2009
|
0.99
|
|
43
|
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
0.99
|
|
44
|
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
|
Leuk Res
|
2006
|
0.98
|
|
45
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
Cancer
|
2003
|
0.98
|
|
46
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
Clin Cancer Res
|
2002
|
0.97
|
|
47
|
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
|
J Clin Invest
|
2016
|
0.96
|
|
48
|
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
|
Am J Hematol
|
2013
|
0.96
|
|
49
|
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
|
Cancer
|
2009
|
0.94
|
|
50
|
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
|
Cancer
|
2010
|
0.92
|
|
51
|
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
|
Clin Cancer Res
|
2005
|
0.91
|
|
52
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Invest New Drugs
|
2008
|
0.91
|
|
53
|
Investigational immunotherapeutics for B-cell malignancies.
|
J Clin Oncol
|
2010
|
0.88
|
|
54
|
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
|
Br J Haematol
|
2010
|
0.87
|
|
55
|
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
|
Leuk Res
|
2005
|
0.86
|
|
56
|
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.85
|
|
57
|
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.83
|
|
58
|
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
|
Br J Haematol
|
2006
|
0.82
|
|
59
|
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.82
|
|
60
|
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.
|
Hum Gene Ther
|
2014
|
0.82
|
|
61
|
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
|
Cancer
|
2004
|
0.81
|
|
62
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
J Clin Oncol
|
2009
|
0.81
|
|
63
|
Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.80
|
|
64
|
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
|
Clin Cancer Res
|
2011
|
0.80
|
|
65
|
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
|
Cancer
|
2012
|
0.79
|
|
66
|
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
|
Cancer
|
2007
|
0.78
|
|
67
|
T-cell prolymphocytic leukemia: a single-institution experience.
|
Clin Lymphoma Myeloma
|
2005
|
0.78
|
|
68
|
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
|
Cancer
|
2005
|
0.78
|
|
69
|
Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
|
Am J Hematol
|
2011
|
0.77
|
|
70
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
|
Cancer
|
2014
|
0.76
|
|
71
|
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
|
J Blood Med
|
2010
|
0.75
|
|
72
|
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
|
J Clin Oncol
|
2007
|
0.75
|
|
73
|
New aspects of the treatment of chronic lymphocytic leukemia.
|
Curr Hematol Malig Rep
|
2006
|
0.75
|
|
74
|
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
|
Cancer
|
2003
|
0.75
|